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Summary
Background Vaccines and prophylactic antibodies against respiratory syncytial virus (RSV) are in development and 
likely to be available in the next 5–10 years. The most efficient way to use these products when they become available 
is an important consideration for public health decision makers.
Methods We performed a multivariate regression analysis to estimate the burden of RSV in children younger than 
5 years in England (UK), a representative high-income temperate country, and used these results to assess the 
potential effect of different RSV immunisation strategies (targeting vaccination for infants, or pregnant women, or 
prophylactic antibodies for neonates). We did a cost-effectiveness analysis for these strategies, implemented either 
separately or concurrently, and assessed the effect of restricting vaccination to certain months of the year.
Findings We estimated that RSV is responsible for 12 primary care consultations (95% CI 11·9–12·1) and 
0·9 admissions to hospital annually per 100 children younger than 5 years (95% CI 0·89–0·90), with the major 
burden occurring in infants younger than 6 months. The most cost-effective strategy was to selectively immunise all 
children born before the start of the RSV season (maximum price of £220 [95% uncertainty interval (UI) 208–232] per 
vaccine, for an incremental cost-effectiveness ratio of £20 000 per quality-adjusted life-year). The maximum price per 
fully protected person that should be paid for the infant, newborn, and maternal strategies without seasonal 
restrictions was £192 (95% UI 168–219), £81 (76–86), and £54 (51–57), respectively.
Interpretation Nearly double the number of primary care consultations, and nearly five times the number of 
admissions to hospital occurred with RSV compared with influenza. RSV vaccine and antibody strategies are likely to 
be cost-effective if they can be priced below around £200 per fully protected person. A seasonal vaccination strategy is 
likely to provide the most direct benefits. Herd effects might render a year-round infant vaccination strategy more 
appealing, although it is currently unclear whether such a programme would induce herd effects.
Funding UK National Institute for Health Research.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Respiratory syncytial virus (RSV) is a highly seasonal 
respiratory virus (the season runs from from late autumn 
to early spring).1 Exposure to RSV does not lead to long-
lasting protection and hence people can have many 
infections over their lifetime.2 Infection mainly leads to 
mild disease, but in very young children (aged 
<6 months), elderly people, and immunocompromised 
patients it can result in serious disease or death.3
Currently, the only effective preventive strategy against 
RSV is passive immunisation with palivizumab, a 
humanised monoclonal RSV-specific antibody. Because 
of its high price, this antibody is only used in the 
highest-risk groups of individuals during the RSV season 
(November to February)—usually young children who 
are born prematurely and have other respiratory or 
cardiac conditions.4,5 However, around 60 RSV vaccine 
and monoclonal antibody candidates are in development, 
16 of which are in clinical trials,6,7 although trial results in 
adults aged 60 years and older for the most advanced 
vaccine candidate (Resolve RSV-F vaccine) have not 
shown efficacy.8 Besides older adults, other potential 
candidates are pregnant women (to protect newborn 
babies through passive immunity), newborn babies 
(through passive immunisation with antibodies), and 
infants. An RSV vaccine could possibly be licensed in the 
next 5–10 years.9 Additionally, at least one extended, half-
life monoclonal antibody designed to protect infants 
from birth, along with at least three maternal vaccines, 
are in clinical trials.6
Decision makers will need to understand the potential 
health and economic effects of the different vaccine and 
antibody options to select strategies that maximise the 
effect of health-care resources. Although the exact 
characteristics of future maternal or infant vaccines or 
prophylactic antibodies for newborn babies are unknown, 
understanding the burden of RSV disease and the drivers 
of vaccine effects and value can help to inform decisions 
about prioritisation of vaccination or antibody strategies, 
and protocols for clinical trials.7 Such analyses can also 
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identify and help to ensure that data are obtained in 
advance about the key drivers of cost-effectiveness.
So far, few studies are available to inform about the 
potential cost-effectiveness of different RSV vaccination 
strategies10 and the need for further cost-effectiveness 
information has been identified as a priority by WHO’s 
Strategic Advisory Group of Experts on Immunisation.11 
To help to address this need, we present a detailed 
analysis of the disease burden of RSV and the associated 
health-care costs in England (UK). We then used England 
as an example of a high-income country in the temperate 
zone that is considering RSV vaccination in the future. 
This allowed us to illustrate general principles and to 
explore the potential effect and cost-effectiveness of 
different vaccine and antibody strategies to protect young 
children in high income, temperate climates with a 
similar epidemiology to England.
Methods
Disease burden estimation
Most people who present to health-care services with 
respiratory symptoms are not routinely tested for RSV, so 
the incidence of primary care attendances and hospital 
admissions for RSV has to be inferred. We used a 
statistical regression model12 to ecologically link clinical 
attendances for acute respiratory infection to organisms 
detected in routine clinical microbiological testing, based 
on temporal trends in both datasets, similar to our work 
estimating the burden of seasonal influenza.12 Similar 
methods have been previously used to explore the burden 
of seasonal organisms, including RSV, influenza virus, 
and rotavirus.13,14 We synthesised information from 
general practice attendances and hospital admissions for 
acute respiratory symptoms and positive laboratory 
reports for respiratory pathogens with data from the 
scientific literature15 to explore the detailed age 
distribution of these clinical attendances in children 
younger than 5 years. Full details of our methods are in 
the appendix (p 1).
Economic model
We used a static cohort model (ie, a model that does not 
account for the indirect or herd effects of vaccination) to 
explore the potential direct effect of paediatric 
vaccination or long-lasting monoclonal antibody use on 
its recipient (appendix p 5). We used the results of the 
model to estimate the net cost and cost-effectiveness of 
the interventions. We estimated the maximum cost-
effective price (MCEP) per fully protected individual that 
could be paid for both the purchase and the 
administration costs of a course of vaccines or 
prophylactic antibodies (including any required booster 
doses), so as not to exceed the threshold of £20 000 per 
quality-adjusted life-year (QALY) gained, which is 
commonly used as a measure of cost-effectiveness in 
England.16 This value is close to the UK’s gross domestic 
product per capita, which has been suggested17 as a 
possible threshold to use for an intervention to be 
deemed very cost-effective. The maximum price payable 
for each fully vaccinated individual for a range of 
assumptions on vaccine efficacy is in the appendix (p 10). 
Further details including cost-related and health-related 
quality-of-life parameters are in table 1, and the appendix 
(p 9).
Research in context
Evidence before this study
Respiratory syncytial virus (RSV) disease is the primary 
contributor to childhood lower respiratory tract infections. 
More than 60 biological candidates for RSV prophylaxis 
(vaccines and prophylactic monoclonal and polyclonal 
antibodies) are undergoing development, of which more than 
25% have progressed to human trials, and one or more is likely 
to be licenced in the next 5–10 years. The candidates target 
different patient populations, and the optimum prophylactic 
strategy is yet to be determined. We did a search of the scientific 
literature, based on expert opinions. Despite some previous 
studies separately assessing the incidence of RSV-attributable 
clinical disease, and the economic impact of vaccination, as yet 
there have been no studies that combine this information, and 
few published studies can be used by decision-making bodies to 
assess the cost-effectiveness of different RSV vaccination 
strategies.
Added value of this study
We used data from laboratory reports and on health-care 
attendances for acute respiratory illness to estimate disease 
burden and health-care costs associated with RSV in England 
(UK). The estimates agreed with those from previous studies, 
while providing greater insight into the timing of outbreaks 
and ages most affected. We present the first quantitative 
analysis to highlight how the month of birth affects 
RSV-attributable health-care outcomes in a temperate 
climate. We then assessed the effect and cost-effectiveness of 
various vaccine and antibody strategies in pregnant women 
and young children. We showed that children born 
immediately before the RSV season, which runs from late 
autumn to early spring, have a two-fold higher risk of 
primary-care attendance and a four-fold higher risk of being 
admitted to hospital than children born after the season.
Implications of all the available evidence
Given the difference in these risks between children born before 
and after RSV season, the most cost-effective strategies, and 
ones that have the potential to avert the most severe disease 
and deaths, are those that protect children born just before the 
RSV season, such as maternal vaccination or long-lasting 
prophylactic monoclonal antibodies.
See Online for appendix
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Interventions
We considered vaccination strategies that targeted either 
infants, pregnant women, or neonates. We assumed that 
neonates would be protected either through passive 
immunisation via maternal vaccination, anticipated to 
give 3 months’ protection, or through an extended 
half-life monoclonal antibody administered to newborn 
infants and providing passive immunisation, anticipated 
to give 6 months’ protection. We also considered the 
strategy of vaccinating neonates born in certain months 
of the year only (appendix p 7). Assumptions behind all 
vaccination strategies are in the appendix (p 7).
Statistical analysis
We ran a probabilistic sensitivity analysis, varying the 
number of RSV-attributable cases, costs, and QALYs 
(table 2, appendix). 95% uncertainty intervals (UIs) are 
the result of 10 000 simulations. Additionally, to deter-
mine the sensitivity of our cost-effectiveness estimates to 
different model variables, we ran a sensitivity analysis, 
sequentially altering model parameters from the baseline 
values. We did all analyses with R version 3.2.2.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author (DC) had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication. 
Results
Variations in baseline parameters are in table 1. Results 
from the regression model suggested that 352 570 (16%) 
of 2 217 400 acute respiratory general practitioner (GP) 
consultations and 26 400 (22%) of 122 100 admissions to 
hospital for acute respiratory conditions are attributable 
to RSV in children younger than 5 years (table 2). We 
estimated that RSV is responsible for around 12 primary 
care consultations (95% CI 11·86–12·12) and 
0·9 admissions to hospital annually per 100 children 
younger than 5 years (95% CI 0·89–0·90), with the major 
burden occurring in infants younger than 6 months 
(table 2, figure 1). In children younger than 6 months, 
RSV accounted for more than half of all admissions to 
hospital for acute respiratory conditions and for more 
than 70% of those admissions occurring between October 
and January (table 2). We estimated that there were 
around 25 deaths (95% CI 24·32–25·44) in children 
younger than 5 years (table 2). Although proportionally, 
the number of RSV-attributable outcomes was higher in 
children younger than 6 months, in absolute terms most 
of the burden occurred in children aged 6 months to 
5 years (table 2).
RSV is extremely seasonal, with peaks of incidence in 
December and January that predominantly affected 
children younger than 6 months (appendix p 3). Children 
born in winter had more RSV-attributable GP 
consultations and admissions to hospital (figure 1), and a 
higher proportion of their primary care outcomes 
occurred when they were younger than 6 months (dark 
red shading in figure 1), similar to that previously 
reported for RSV-attributable laboratory reports.1 The 
incidence of RSV-attributable GP consul tations in the 
first year of life fluctuated between 13·9 per 100 children 
born in March up to 27·4 per 100 children born in 
November (and similarly from 1·55 per 100 births to 
6·47 per 100 births for admissions to hospital). 
Health-care costs for RSV in children younger 
than 5 years are £54 million annually (95% UI 
50 million–57 million) or £87·58 annually per child 
(82–93). Most of this cost (£37 million) resulted from RSV-
attributable admissions to hospital (including admissions 
to intensive care, which are assumed to be more likely 
in preterm infants), and was split approximately 
equally between children younger than 6 months 
(£19·1 million [95% UI 18·7 million–19·4 million]) 
and children aged between 6 months and 5 years 
(£18·4 million [16·3 million–20·4 million]). RSV-
attributable GP consultations cost the health-care service 
Base case value Lower limit Upper limit
Vaccine efficacy* 70% 50% 100%
Age of infant vaccine administration 3 months 2 months 4 months
Duration of maternal antibody protection 3 months 2 months 4 months
Duration of neonatal prophylactic antibody protection 6 months 4 months 8 months
Multiplier for deaths 1·0 0 2·0
Multiplier for QALYs 1·0 0·8 1·2
Multiplier for costs 1·0 0·8 1·2
Discounting 3·5% 1·5% 3·5%
QALY=quality-adjusted life-year.*Because there were no available data to inform on vaccine efficacy, we chose a mid-
range efficacy value. 
Table 1: Base case parameters for the cost-effectiveness model and variations used in the sensitivity analysis
Age less than 6 
months
Age 6 months to less 
than 5 years 
Age less than 5 years
GP consultations 64 570  
(63 700–65 430)
288 000  
(284 230–291 770)
352 570  
(348 700–356 440)
Incidence per 100 population 21·42  
(21·13–21·70)
10·92  
(10·77–11·06)
11·99  
(11·86–12·12)
Admissions to hospital 13 250  
(13 200–13 310)
13 150  
(13 020–13 280)
26 400  
(26 270–26 550)
Incidence per 100 population 4·4 (4·38–4·41) 0·5 (0·49–0·50) 0·9 (0·89–0·90)
GP consultations leading to 
hospital admissions
20·53% 4·57% 13·00%
Deaths in hospital 7·49  
(7·19–7·79)
17·39  
(16·92–17·86)
24·88  
(24·32–25·44)
Incidence per 100 population 0·00248  
(0·00238–0·00258)
0·00066  
(0·00064–0·00068)
0·00085  
(0·00083–0·00087)
Data are n (95% CI), incidence per 100 population (95% CI), or n (%). 95% CIs were used to fit a normal distribution in 
the probabilistic sensitivity analysis. 
Table 2: Estimated number of annual general practitioner (GP) consultations, admissions to hospital, 
and deaths in hospital attributable to respiratory syncytial virus in children younger than 5 years
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£16 million annually (95% UI 14 million–19 million), with 
£13 million (82%) of the total cost (£16 million) for older 
children and £3 million (18%) for children younger than 
6 months. Almost 70% (3526 of 5221) of QALYs lost 
stemmed from events associated with GP consultations 
and almost 75% (3841 of 5221) of QALY losses were caused 
by outcomes in older children.
Results of vaccination are shown for a vaccine with 
100% efficacy to present the maximum possible effect; 
however, the proportional effect from different strategies 
was the same regardless of the vaccine efficacy (figure 2). 
Most of the cost-savings from any strategy resulted from 
averted admissions to hospital and intensive care 
(62% using the infant strategy and 86–88% when 
protecting newborn babies; figure 2), despite most of the 
averted cases being in primary care (95%, 83%, and 80% 
for infant, newborn, and maternal strategies, respectively). 
QALY gains from all strategies were driven largely by 
averting GP consultations (73% of gains for an infant 
strategy and 47% and 43% for newborn and maternal 
strategies, respectively; figure 2). For all strategies, just 
over 10% of the QALYs gained were from avoidance of 
RSV-attributable deaths in hospital. With the same vaccine 
efficacy, a newborn strategy averted many more RSV-
attributable outcomes in babies younger than 6 months 
than a programme for infants aged 3 months and older.
Figure 1: Outcomes attributable to respiratory syncytial virus by month of birth
(A) General practitioner (GP) consultations, (B) admissions to hospital.
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Figure 2: Cases of respiratory syncytial virus averted and costs or QALYs saved for different vaccination strategies with complete vaccine efficacy
Data given per 100 annual births for (A) general practitioner (GP) consultations averted,(B) hospital admissions averted, (C) deaths in hospital averted, (D) health-care 
costs saved, (E) QALYs saved, and (F) maximum cost-effective price (MCEP) of vaccination strategy. M=maternal immunisation strategy. N=newborn passive 
immunisation strategy. C=infant strategy, N+C=newborn and infant strategies. ICU=intensive-care unit. QALY= quality-adjusted life-year.
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In the base case, the maximum price payable per fully 
protected person that should be paid for infant, newborn, 
and maternal vaccination strategies without seasonal 
restrictions was £192 (95% UI 168–219), £81 (76–86), and 
£54 (51–57), respectively.
The MCEP for a strategy that combined a newborn 
and infant programme was £246 (95% UI 219–275). 
However, if a newborn programme was already in place 
(hence reducing disease burden and thus the benefit of 
any further immunisation strategies), then the MCEP of 
an infant vaccine would drop from £192 to £165 (143–190). 
Likewise, if an infant programme was already in place, 
then the MCEP for a newborn strategy decreased from 
£81 to £54 (51–57).
Regardless of the actual cost of an immunisation 
strategy or its efficacy, because of the extreme seasonality 
of RSV, and its propensity to infect very young children, a 
strategy to protect newborn babies is most cost-effective 
if it is only administered during certain months of the 
year. In the UK, the most cost-effective strategy was to 
protect only neonates born in November (before the start 
of the RSV season; MCEP of £220 [95% UI 208–232] per 
fully protected newborn infant). We noted that nine of 
the top ten most cost-effective strategies involved 
restricting prophylaxis to neonates born in only 4 months 
(or fewer) of the year, and who were born before the peak 
in RSV incidence (figure 3).
The model was most sensitive to vaccine efficacy, and 
for the maternal or newborn strategy, to the duration of 
vaccine protection (figure 4). It was difficult to predict at 
this stage the potential effect that an RSV vaccine or 
antibody might have on infection transmission and 
hence indirect (herd) benefits, so the results presented 
here provide a conservative lower bound of the maximum 
price to pay per protected person, in the absence of 
consideration of herd effects. To estimate the maximum 
benefit that might be conferred through indirect effects, 
we made the assumption that introduction of a vaccine 
would completely eliminate disease transmission and 
hence disease in all children younger than 5 years 
(including those too young to receive the vaccine). Under 
this assumption, the maximum price for a full course 
and administration of a vaccine was £246 (220–276).
Discussion
There is a large and costly RSV disease burden in 
children younger than 5 years, especially infants younger 
than 6 months (particularly for admissions to hospital) 
and in the winter months. Indeed, in children younger 
than 5 years RSV is responsible for nearly twice as many 
GP consultations and nearly five times as many 
admissions to hospital as influenza, for which paediatric 
vaccination has been found to be cost-effective.18 RSV 
accounts for more than 75% of infants admitted to 
hospitals for respiratory conditions between the 
beginning of November and the end of January, 
consistent with other studies showing RSV to be a 
leading cause of infant admissions to hospital.19 We have 
shown how RSV-attributable health-care outcomes vary 
based on month of birth, with children born just before 
the start of the RSV season having double the risk of an 
RSV-attributable GP consultation and more than a 
four-fold higher risk of an RSV-attributable admission to 
hospital in their first year of life than those born after the 
RSV season. The general trends and conclusions for 
England are likely to be similar in high-income temperate 
countries with similar epidemiology, widespread health 
services and existing, well supported vaccination 
programmes.
Our estimates for RSV-attributable admissions to 
hospital are in line with other UK estimates,13,20,21 and 
many reported in western Europe,22,23 but lower than 
estimates reported for Spain (a full comparison is in the 
appendix p 8). Our findings about the marked seasonality 
of RSV disease agree with those from a study in England1 
showing that infants born just before or during the RSV 
season had a much higher risk of laboratory-confirmed 
RSV in their first year than those born just after the RSV 
season.1
Around 20% of infants visited GPs for RSV-
attributable consultations in the first 6 months of life, 
and a fifth of these were admitted to hospital. Although 
the burden of RSV decreased as infants matured, nearly 
half of all children aged 6 months to 5 years visited 
GPs for RSV-attributable respiratory illnesses, with 
5% resulting in admissions to hospital. These estimates 
Figure 3: Ten most cost-effective periods over which to offer newborn 
vaccination or prophylactic antibodies against respiratory syncytial virus
Red shading shows the birth months of the children that are most cost-effective 
to protect via a newborn strategy. Prices are per fully protected child for 
vaccination or prophylactic antibodies. All of the ten most cost-effective 
programmes involved protecting newborn infants for 5 months or less of the 
year, the top nine protected for 4 months or less, and the top 
eight recommended protecting children born in November.
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agree with those from a study13 based on a restricted 
regression analysis of UK data that only incorporated 
laboratory reports for influenza and RSV rather than all 
respiratory pathogens.
One of the limitations of our study was that our disease 
estimates were based on statistical models, similar to 
those used to understand the burden of other 
respiratory12,13 and diarrhoeal diseases.14 Therefore the 
normal caveats apply, such as difference in sensitivity 
between tests, reporting bias, testing practices, and 
unattributable changes over time. However, our RSV 
model was based on previous work testing nine models 
incorporating adjustments suggested by others24,25 on six 
different age groups and selected the best-fitting model.12 
Our assumptions of the effects that RSV infection has on 
quality of life, although from a previous cost-effectiveness 
analysis,10 were based on expert opinion rather than data. 
Indeed, RSV-averted deaths through vaccination might 
have occurred in children who had a lower quality of 
life or shorter life expectancy than average because of 
other comorbidities, and this differential might make 
vaccination less cost-effective. Future cost-effectiveness 
studies could benefit from better understanding of the 
effect of RSV disease on quality of life in young children, 
more detailed information on RSV incidence by month of 
birth in children younger than 1 year, and more detailed 
information about disease in preterm infants. Our 
burden estimates were based on data from 2001 to 2008, 
and although they were in agreement with other 
estimates, all were done before the introduction of 
paediatric vaccination for influenza; thus, future studies 
are required to consider the implications of this policy 
change on RSV burden.
The exact effect of an RSV vaccine or monoclonal 
antibody depends heavily on the age at which it can be 
given, and the age profile of RSV disease burden in very 
young infants. We based our analysis on several existing 
studies which showed RSV-associated admissions to 
hospital peaked at around 2 months of age, and 
decreased thereafter.15,26,27 However, RSV probably 
induces more severe disease in younger age groups28 
and therefore the age profile of milder disease might be 
different. Understanding both the age-distribution and 
seasonality of RSV disease is key to selecting the best 
preventive strategy; hence, further direct active 
surveillance is needed to get better estimates. 
Additionally, although the burden of RSV in low-income 
and middle-income countries is substantial,22 further 
work is needed to assess the effect of interventions in 
these settings because of differences in seasonality of 
disease, access to care, resources available to pay for 
interventions, and population comorbidities.
Since neither the mechanism of action or the efficacy of 
RSV-immunisation strategies for either newborn babies 
or infants are known, a transmission model was not used 
in this analysis, therefore herd effects that might protect 
infants too young to be vaccinated, other unvaccinated 
children, and older individuals could not be assessed. If 
an RSV vaccine can prevent transmission as well as 
disease, the vaccine is likely to be even more cost-effective 
than our analysis suggests, and the results of future 
clinical trials will be essential to determine vaccine efficacy 
for each strategy. Using an assumption of complete 
disease elimination in children younger than 5 years, we 
concluded that the maximum price payable for the full 
purchase and administration of an RSV-immunisation 
programme would be £244. Herd effects might thus 
render a year-round vaccination strategy more cost-
effective than a seasonal one, since a seasonal strategy is 
unlikely to elicit these effects. Hence, once suitable data 
on vaccine mechanisms become available the cost-
effectiveness should be reassessed using a dynamic 
model. Additionally, because of the uncertainties described 
above, and the uncertainty in vaccine price, we did not 
use the traditional approach of comparing the cost-
effectiveness of different options incrementally to each 
other, since this would require knowing the cost of each 
option. Once further details of the vaccines become 
available, a full incremental cost-effectiveness analysis of 
all options together would be helpful.
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Figure 4: Sensitivity to model parameters of cost-effectiveness calculations for respiratory syncytial virus vaccination
(A) Infant strategy. (B) Newborn infant strategy. (C) Maternal strategy. Bars show by how much the maximum cost-effective price changes from its base case level when model parameters are varied. 
Changing the discounting strategy, or excluding deaths from the model, had little effect on the maximum cost-effective price (MCEP) estimates. Similarly, modifying the costs or quality-adjusted 
life-years (QALYs) associated with each health-care outcome had little effect on model estimates.
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We did not consider the vaccination of children older 
than early infancy. Such a strategy would not directly 
protect infants at the age of highest disease incidence, 
but might have a large effect on disease by protecting the 
younger group through herd (indirect) protection.
The most cost-effective strategy assessed was a seasonal 
strategy that protected children who are born just before 
the RSV season from birth for the first few months of 
life. The exact month of vaccination should be determined 
on the basis of the epidemiology of each country. Such a 
seasonal vaccination strategy would probably only be 
feasible for a single-dose immunisation strategy, either 
given to the mother before birth, or to a child in the first 
few weeks of life. This suggests that efforts focused on 
developing an efficacious maternal vaccine, or a birth 
dose of a long-lasting monoclonal antibody, and on 
investigating the potential for vertical protection are 
well placed. Single-dose prophylactic antibodies have 
completed phase 1 trials in adults29 and are in phase 1b 
and 2a clinical trials in infants.6
Under certain conditions, protecting older infants 
would be more cost-effective than protecting neonates. 
However, these conditions only hold under optimistic 
assumptions about an infant vaccine—ie, that it will 
confer full protection from age 6 months to 5 years 
compared with the rapidly waning protection from a 
newborn dose of monoclonal antibody or maternal 
immunisation. Additionally, we showed that most QALY 
gains from vaccination were attributable to avoiding GP 
consultations rather than hospital admissions and 
deaths. This result drives the greater relative economic 
value of infant strategies compared with newborn or 
maternal strategies, even though maternal strategies 
might prevent more severe RSV cases. Although, as 
Black argues30 the goal of immunisation programmes is 
primarily to prevent severe disease and death.
Severe RSV infection early in life might be linked to 
later development of chronic conditions such as 
wheezing and asthma.31 Such long-term chronic 
conditions can be influential in cost-effectiveness 
analyses because of their long-term implications. 
However the relation between RSV infection and 
long-term outcomes is uncertain and has only been most 
clearly described for preterm infants.32 This additional 
complication was not included in our analysis but should 
be considered, particularly when more is known about 
the likely groups indicated for vaccination and the 
parameters of the relation between RSV and its sequelae.
RSV burden is substantial in children under 5 years, 
particularly in young infants. Passive or active immun-
isation directed at pregnant women, neonates, or infants 
could reduce this burden and would be good value for 
money if priced appropriately. There is potential for an 
RSV vaccine that protects infants and young children to 
be cost-effective because of the high disease burden in 
these groups. A maternal or newborn vaccination strategy 
is likely to avert the most severe disease and deaths, 
especially if it can be targeted at protecting infants born 
during the RSV season between late autumn and early 
spring. Vaccination of older children with a long-lasting 
vaccine might avert more health-care costs and episodes 
of mild disease. Our conclusions are based on ecological 
analyses of syndromic and laboratory data with economic 
modelling using a range of characteristics of potential 
prophylactic interventions. They will need to be validated 
when results from clinical trials and post-licensure 
studies become available.
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